Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HCV Sales Drive AbbVie's Great Quarter, But Gains Won't Last

Executive Summary

Q1 earnings far outpaced expectations due to the successful launch for new hepatitis C drug Mavyret, but with the HCV market overall in decline those gains won't last and won't make up for the looming loss of Humira revenue.

You may also be interested in...



AbbVie HCV Revenue Surprises Again, But Falloff Is Coming

Led by eight-week, pan-genotypic combo Mavyret, AbbVie’s HCV franchise grows despite a declining US market that has taken a toll on competitors Gilead and Merck. Still, AbbVie expects a falloff in the third quarter.

AbbVie HCV Revenue Surprises Again, But Falloff Is Coming

Led by eight-week, pan-genotypic combo Mavyret, AbbVie’s HCV franchise grows despite a declining US market that has taken a toll on competitors Gilead and Merck. Still, AbbVie expects a falloff in the third quarter.

Pharma Q2 Results Preview: Celgene, Amgen, Allergan And AbbVie

With the FDA updating its stance on interchangeability, analysts will be pushing Amgen and AbbVie on how the policy changes will affect biosimilar competition. Celgene and Allergan will be under pressure for R&D updates; Allergan remains in the hot seat on its pipeline growth strategy from activist investors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

WI964842

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel